| Name | Title | Contact Details |
|---|
Electrify America, LLC is a prominent electric vehicle (EV) charging network in the United States, established in 2016 as a subsidiary of Volkswagen Group of America. The company aims to promote Zero-Emission Vehicle (ZEV) adoption by creating a nationwide network of ultra-fast and convenient EV charging stations. As of August 2024, Electrify America operates over 950 charging stations with more than 4,250 DC fast charging connectors, making it the largest open DC fast-charging network in the country. The company focuses on providing reliable and accessible hyper-fast charging solutions, supporting multiple connector types, including CCS and CHAdeMO, with plans to add Tesla’s North American Charging Standard (NACS) connectors in 2025. Electrify America is committed to sustainability, ensuring that all energy supplied to drivers is backed by 100% renewable energy certificates, and aims for a net zero carbon footprint. Headquartered in Reston, Virginia, the company employs around 300 people and actively engages in community education to promote equitable electrification.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Safety National is a prominent specialty insurance and reinsurance provider with over 80 years of experience. As a wholly-owned subsidiary of Tokio Marine Holdings, Inc., it benefits from the strength of one of the worlds top insurance groups. The company focuses on building strong relationships and providing long-term solutions for its customers. Safety National specializes in long-term insurance and reinsurance solutions, particularly in managing high-exposure claims. It offers MAP Client Services®, a suite of online risk control resources designed to help policyholders improve their safety and compliance programs. The company is highly rated by major financial agencies, holding an A++ rating from A.M. Best and an A+ rating from Standard & Poor’s. The corporate culture at Safety National emphasizes diversity, equity, and inclusion, aiming to reflect the communities it serves. The company is committed to corporate social responsibility through sustainability practices and charitable efforts. Safety National actively seeks talented individuals who share its dedication to excellence and growth.
We understand that flood insurance can be expensive but at Superior Flood, we can help you save 20-50 percent on flood insurance coverage. Call us today.